Targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers
The goal was to educate participants on state of the art research and science behind targeting EGFR/HER family in three most frequent cancer types. The Symposium hosted approximately 200 attendees in order to allow maximum interactions with faculty. A plenary discussion on principles of signalling transduction, mechanisms of primary and secondary resistance to targeted therapy, preclinical models and biomarkers dissection, was implemented by discussion within parallel sessions on dysregulation of HER receptors and subsequent potentials for targeting by different strategies in breast, lung and colorectal cancers. Additional panel expert discussion brought synthesis on different aspects elaborated during the presentations and confronted the complexity of current challenges in the field with intention to provide a future perspective for innovative collaborations between academia and pharma.
Download the Programme Book
Signalling Pathways 2013 Scientific Manuscript
Read the editorial article on ESMO first signalling pathways symposium and personalised cancer medicine published by Prof. Martine Piccart in the August 2013 issue of Annals of Oncology.